Indonesia Brain Cancer Therapeutics Market

Indonesia Brain Cancer Therapeutics Market Executive Summary

Indonesia Brain Cancer Therapeutics Market valued at $14 Mn in 2022, projected to reach $31 Mn by 2030 with a 10.6% CAGR.

The abnormal proliferation of brain cells serves as an indication of brain cancer, where these cells exhibit characteristics that can be either malignant (cancerous) or benign (non-cancerous). While the exact cause of brain cancer remains unclear, identified risk factors include exposure to ionizing radiation and a family history of brain tumors. Common symptoms associated with a brain tumor include headaches, gradual sensory decline, issues with balance, speech impediments, and hearing difficulties. The manifestation of these symptoms varies depending on factors such as the tumor’s size, location, and growth rate. Treatment approaches for brain cancer are determined by the tumor’s type, location, and size, with frequently utilized methods including radiosurgery, chemotherapy, radiotherapy, surgery, and the use of carmustine implants.

In Indonesia, the 5-year prevalence of brain and other Central Nervous System (CNS) tumors stands at 946,088. This figure reflects the cumulative number of individuals living with these conditions over five years. In addition, there were an estimated 396,914 new instances of cancer in the nation, with 183,368 cases affecting men and 213,546 cases affecting women. According to reports, Indonesia has an age-standardized incidence rate of 141.1 per 100,000 individuals for cancer. This rate indicates that 1.4% of the total population has received a cancer diagnosis and offers a standardized measurement that considers demographic age disparities. Unfortunately, there are still 234,511 documented cancer-related fatalities in the area, making cancer a major cause of death.

DSP-0390, an experimental Emopamil-binding Protein (EBP) Inhibitor, has been granted Orphan Drug Designation to Sumitomo Pharma Oncology, a clinical-stage firm. GBM is a type of high-grade glioma that affects the brain. This designation underscores the profound need for novel brain cancer treatment. A Phase 1 clinical trial is presently being carried out in the US and Japan to assess the drug's safety and effectiveness in treating patients with high-grade gliomas.

Market Dynamics

Market Growth Drivers

Rising Incidence of Brain Tumours: Due to a number of circumstances, the frequency of brain tumors is rising in Indonesia. The risk is larger among the aging population because the chance of getting these tumors increases with age. The rising incidence of brain tumors is also attributed to alterations in lifestyle that include smoking, poor diets, and increased exposure to environmental pollutants. Additionally, this tendency is largely due to advances in diagnostic tools that make it possible to discover brain cancers early. This early detection highlights the market's growth trajectory by increasing demand for brain cancer therapy as well as facilitating timely medical intervention.

Technological Advancements and Drug Pipeline: Pharmaceutical companies in Indonesia are proactively allocating resources to research and development efforts aimed at creating innovative drugs for brain cancer, with a specific focus on targeted therapies and immunotherapies. The rise in clinical trials for these promising new drugs not only expands the pool of potential treatments but also provides a broader range of options for patients. Furthermore, the local production of generic versions of well-established drugs is contributing to a reduction in costs and overcoming accessibility barriers, ensuring a more widespread availability of these critical treatments.

Growing Awareness and Demand for Improved Treatment Outcomes: Media campaigns and patient advocacy groups are driving the public's growing awareness of brain cancer and the variety of treatment options available. Patients are becoming more and more motivated to seek longer survival times and higher quality of life, which is fuelling the desire for more effective treatments.

Market Restraints

Regulatory Hurdles: The rigorous regulatory demands and approval procedures may present obstacles in the development and introduction of novel drugs for brain cancer treatment, potentially causing delays in their market entry.

Cost and Affordability: Newly developed immunotherapies and tailored treatments often come with high costs, making them unavailable to many patients, especially those living in rural areas. Even if more people have access to healthcare insurance, the costs of expensive new medications or cutting-edge treatment plans could not be fully covered. Patients frequently incur significant out-of-pocket expenses, which can cause financial hardship and, in rare circumstances, lead to treatment termination.

Limited Efficacy of Current Treatments: The effectiveness of current treatments for brain cancer might be constrained, emphasizing the necessity for groundbreaking innovations to markedly enhance patient outcomes. This constraint could potentially influence the market prospects of presently available drugs.

Healthcare Policies and Regulatory Landscape

In Indonesia, the Ministry of Health (Kemenkes) and the National Agency of Drug and Food Control (Badan Pengawas Obat dan Makanan-BPOM) work together to control the regulatory environment for the treatment of pharmaceuticals. BPOM is essential to approving and overseeing pharmaceutical marketing authorizations since it guarantees the products' quality, safety, and efficacy. The Ministry of Health establishes broad guidelines for healthcare, influencing the standards these medications follow. The national health insurance program, known as Jaminan Kesehatan Nasional, or JKN, impacts the accessibility and payment of medications used to treat brain cancer. The review and approval procedures are also impacted by continuing efforts to create health technology assessment mechanisms and laws controlling clinical trials and research.

Competitive Landscape

Key Players

• Roche
• Novartis
• Pfizer
• Merck
• AstraZeneca
• Bristol Myers Squibb
• Eli Lilly
• Sanofi
• Johnson & Johnson
• Takeda